Skip to main content
Premium Trial:

Request an Annual Quote

Aspira Biosystems, Genzyme Molecular Oncology


Aspira Biosystems of San Francisco has received US Patent No. 6,458,599, “Compositions and methods for capturing, isolating, detecting, analyzing and quantifying macromolecules.” The patent claims broad methods of making imprint compositions capable of capturing macromolecules of interest. The invention encompasses solidifying a fluidic material, such as a mixture of polymers, which form shaped cavities in the presence of a template molecule that corresponds to a portion of the macromolecule. Once the polymers are solidified, the template molecules are removed, producing cavities that are capable of capturing the target macromolecule. Under the trade name ProteinPrint, Aspira is applying this technology to make arrays of protein capture agents for detecting specific proteins in biological samples.

Genzyme Molecular Oncology of Framingham, Mass., has received Japanese Patent No. 3,334,806. According to the company, the patent covers the methodology by which SAGE (Serial Analysis of Gene Expression) identifies and measures gene expression. Genzyme received a US patent covering SAGE in 1997.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.